Acute respiratory distress syndrome is a major cause of respiratory failure in critically ill patients. Despite extensive research into its pathophysiology, mortality remains high. No effective pharmacotherapy exists. Based largely on numerous preclinical animal studies, administration of mesenchymal stem or stromal cell (MSC) as a therapeutic for acute lung injury (ALI) holds great promise, and Phase I and II clinical trials are currently under way internationally. However, concern for the use of stem cells, specifically the risk of iatrogenic tumor formation, as well as the prohibitive cost of production, storage, and distribution of cells in bone marrow transplant facilities, may limit access to this lifesaving therapy. Accumulating evidence now suggest that novel stem cell-derived therapies, including MSCconditioned medium and extracellular vesicles (EVs) released from MSCs, might constitute compelling alternatives. The current review summarizes the preclinical studies testing MSC EVs as treatment for ALI and other inflammatory lung diseases. While certain logistic obstacles limit the clinical applications of MSCconditioned medium such as the volume required for treatment and lack of standardization of what constitutes the components of conditioned medium, the therapeutic application of MSC EVs remains promising, primarily due to ability of EVs to maintain the functional phenotype of the parent cell. However, utilization of MSC EVs will require large-scale production and standardization concerning identification, characterization, and quantification.
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A cute respiratory distress syndrome (ARDS), the clinical manifestation of acute lung injury (ALI), is a major cause of acute respiratory failure where mortality remains as high as 33% to 48% in critically ill patients. 1, 2 The most common triggering event for
ARDS is severe sepsis from either a pulmonary or a nonpulmonary source, accounting for 79% of the cases. 1 However, various other inciting events including aspiration, toxic inhalation, lung contusion, acute pancreatitis, trauma, transfusion, burn injury, and cardiopulmonary bypass surgery can cause ARDS. 3 Once triggered by infectious, chemical, or mechanical insult, the pathophysiology of ARDS results from complex interaction between the immune system and the alveolarcapillary barrier. Acute inflammatory response after the insult affects endothelial and epithelial Type I and II cells in the alveoli. Damage to alveolar endothelium and epithelium directly increase the permeability of the alveolar-capillary barrier and damage to Type II cell impair pulmonary surfactant secretion and alveolar fluid clearance. The increased permeability of the alveolar-capillary barrier and impaired alveolar clearance result in pulmonary edema, which eventually cause impaired gas exchange and hypoxemia. 4 Currently, there is no available pharmacotherapy based on the pathophysiology 
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Recently, mesenchymal stem cells (MSC) have been regarded as a promising approach for ARDS because of their ability to attenuate the major pathologies underlying ALI. MSCs are nonhematopoietic precursor cells from a variety of tissues in adult such as the marrow, adipose tissue, and placenta. MSCs were first described as fibroblastlike cells of the marrow in 1968. 9 The definition of MSCs was established by the International Society of Cellular Therapy in 2006 as the following criteria: 1) adherence to plastic-MSCs must be adherent to plastic under standard tissue culture conditions; 2) specific surface antigens-MSCs must express certain cell surface markers such as CD105, CD90, and CD73, but must not express CD45, CD34, CD14 or CD11b, CD79a, CD19, or HLA-DR; and 3) multipotent differentiation-MSCs must be able to differentiate into osteoblasts, adipocytes, and chondroblasts under standard in vitro conditions. 10 The therapeutic effects of MSCs were initially thought to derive from their engraftment in the injury site and regeneration. However, the presence of MSCs in the injured organ is only transient, and the replacement of the damaged tissues with transdifferentiated stem cells is very limited ( < 5%). 11, 12 The current view is that therapeutic properties of MSCs are derived from soluble factors with paracrine or endocrine effects. [13] [14] [15] The soluble factors include growth factors, anti-inflammatory cytokines, and antimicrobial peptides, which can stabilize the alveolar-capillary barrier, enhance alveolar fluid clearance, and decrease infection. 16 Recent studies have also underscored the new potential role of extracellular vesicles (EVs), small anuclear membrane-bound particles released from MSCs, as a paracrine or endocrine vehicle to deliver various soluble factors with a similar phenotype as the parent cell. [17] [18] [19] [20] [21] Although the preclinical studies for the therapeutic use of MSC-derived EVs in ARDS is still in its infancy, its potential as treatment versus using intact live cells are significant such as: 1) ability to store EVs without the use of preservatives such as dimethyl sulfoxide; 2) no need for a bone marrow transplant facility to store living cells, potentially increasing the number of facilities which can deliver stem cell derived therapy; and 3) potential ability to give multiple doses without significantly effecting the patient's hemodynamic or respiratory variables. In this review, we summarize the biologic basis and the preclinical data available for the potential use of MSC-derived EVs for ALI. [23] [24] [25] [26] [27] [28] As EV transports complex biologic information from donor cells to recipient cells, it can contribute to the maintenance of normal and pathophysiologic conditions. 25, 29 EVs can be classified into exosomes, microvesicles, or apoptotic bodies according to size, biogenesis, and composition. [30] [31] [32] Because there is no consensus on the nomenclature for the type of vesicles, especially for the microvesicles, other names such as shedding vesicles, ectosomes, exosome-like vesicles, nanoparticles, microparticles, and oncosomes have been employed in the literature. Microvesicles are generally heterogeneous in size ranging from 50 to 1000 nm in diameter depending on the state of the cell during release. Whereas, exosomes are relatively homogenous in size with a diameter ranging from 40 to 200 nm. Furthermore, the process of vesicle formation and release from cells also differs between exosomes and microvesicles. Microvesicles are released by direct shedding or budding from the plasma membrane, whereas exosomes are assembled through an invagination process of the endosomal membrane of multivesicular bodies (MVBs) within cells and, then, the fusion of the multivesicular bodies with the plasma membrane resulting in its release. 32 Due to the difference in assembly and release, each of the EV subtypes has its own characteristic surface and intracellular markers. 33 The release of exosomes is often detected within minutes after stimulation while microvesicles are released within seconds after stimulation. Although there can be some uncertainty or overlap for EV subtype markers, CD63 and CD61 are known as common stereotypic markers for exosomes and TyA and C1q for microvesicles. However, despite such differences, both of the two EV subtypes are released upon physiologic or pathologic stimulus and have important effects on cell physiology and pathology by transferring their cargoes to target cells over short or long distances. Some EVs can break down shortly after release and excrete their contents to the extracellular space. The released agents bind their receptors in adjacent cells and provoke rapid responses. [34] [35] [36] Most EVs that maintain their structure longer can travel to target cells, and thus EVs can be found in major body fluids, such as blood, lymph, and cerebrospinal fluid. 33 There are various patterns of the interaction between EVs and the target cells: 1) direct stimulation to target cell through surface-expressed ligands, 2) direct fusion to target cell transferring membrane receptor and luminal material, and 3) uptake of entire EVs by target cell in the endocytosis process. 22 47, 48 Similar to MSCs, the early preclinical studies using MSC-derived EVs in several ALI models are promising and discussed below (Fig. 1) .
DEFINITION AND CHARACTERIZATION OF EVS

Endotoxin-induced ALI
Zhu and colleagues 21 demonstrated the therapeutic efficacy and mechanism of human MSC-derived EVs in a mice ALI model induced by intratracheal administration of Escherichia coli endotoxin. In the study, MSC-derived EVs reduced alveolar inflammation and edema by decreasing the influx of inflammatory cells and total protein levels in the endotoxin-damaged alveolus. In addition, the therapeutic effects of the EVs were comparable regardless of route of administration, intratracheal or intravenous (IV). Elimination of KGF activity found in the EVs using either siRNA or KGF antibody partially abrogated the therapeutic effects of MSC-derived EVs, which suggested that the transfer of KGF mRNA to the target tissue was one of mechanisms of action. KGF, also known as FGF7, is an epithelial-specific growth factor and a major paracrine factor released from MSCs with significant reparative properties. In ALI models, KGF from MSCs has been shown to restore protein permeability and increase fluid clearance in the alveolus after injury. 47, 48 A recent study by Tang and coworkers 49 also demonstrated MSC-derived EVs as a therapeutic agent in endotoxininduced ALI in mice. Intratracheal administration of MSC EVs ameliorated lung inflammation and restored alveolarcapillary permeability after endotoxin-induced injury. Furthermore, administration of the EVs suppressed TNF-α and increased IL-10 secretion in a mouse macrophage cell line (RAW264.7) after endotoxin stimulation. Administration of EVs from Ang-1 SiRNA-transfected MSCs partly abrogated the beneficial effects on alveolar inflammation and permeability in mice as well as immunomodulation in macrophages. Ang-1 is an angiogenic factor that stabilizes endothelial cells during injury, reduces endothelial permeability, and suppresses white blood cell (WBC)-endothelium interactions. Ang-1 is also significantly secreted by MSCs. 47, 48 Recently, Morrison and coworkers 50 demonstrated that MSC-derived EVs protected against endotoxin-induced ALI by altering alveolar macrophage toward an antiinflammatory phenotype with enhance phagocytic activity via EV-mediated mitochondrial transfer. Intratracheal administration of alveolar macrophages treated with MSCderived EVs reduced inflammatory cells recruitment and the levels of TNF-α and protein in the alveolus of mice with endotoxin-induced lung injury. Previously, using MSC as a therapeutic to prevent silica-induced lung inflammation and fibrosis, Phinney and coworkers 51 also found that MSCs shed exosomes that modulated TLR signaling and cytokine secretion in macrophages, in part, by transfer of regulatory microRNAs; miR-451, known to suppress TNF and macrophage migration inhibitory factor, was highly abundant in MSC-derived exosomes, suggesting that the possible transfer of miR-451 to and increased expression in macrophages inhibited TNF secretion in response to silica. The authors also demonstrated that MSC-derived exosomes prevented the recruitment of Ly6C hi monocytes and reduced secretion of profibrotic IL-10 and TGF-β by these cells. Finally, the author found that MSCs managed intracellular oxidative stress by the transfer of depolarized mitochondria by MSCs. MSC-derived vesicles containing the mitochondria were engulfed and reutilized by macrophages, resulting in enhanced bioenergetics. These two studies demonstrated that mitochondrial transfer by MSC-derived EVs was a significant mechanism for its therapeutic effect. It was already known that MSC was able to transfer mitochondria to the alveolar epithelium 52 and macrophage 53 through direct cell contact via tunneling nanotubes, but, now, MSC-derived EVs was also able to transfer mitochondria to recipient cells.
Bacteria-induced ALI
Monsel and colleagues 46 instilled live E. coli bacteria into trachea, which caused bacterial pneumonia and lung injury, to demonstrate the therapeutic effect of MSC-derived EVs on bacteria-induced ALI. The authors demonstrated that IV administration of MSC-derived MVs improved survival and reduced the bacterial load, inflammation, and protein permeability in the injured alveolus with live E. coli. The therapeutic effects were mediated in part by KGF. More specifically, MSC-derived EVs increased the phagocytosis of bacteria and suppressed TNF-α secretion in monocytes stimulated with bacteria. MSC-derived EVs also restored intracellular ATP levels in injured alveolar epithelial Type II cells. These results confirmed that the mechanisms of MSC-derived EV are as variable as those of MSCs including anti-inflammatory and antimicrobial and with direct metabolomic effects. Furthermore, the EVs isolated from stimulated MSCs with TLR3 agonist further increased phagocytosis, decreased TNF-α secretion, and increased IL-10 secretion in monocytes compared to naïve MSCderived EVs in mice with bacteria-induced ALI, suggesting that the contents and effects of the MSC-derived EVs can be modified by changing the phenotype of the parent cell. Finally, Monsel and coworkers also found that the surface receptor CD44 was crucial for incorporation of MSC-derived EVs into injured monocytes and alveolar epithelial Type II cells. CD44 is the principal surface receptor for hyaluronic acid, a major extracellular matrix component. 54 It is expressed in almost every cell type including MSCs and associated with the regulation of cell proliferation, differentiation, survival, migration, and trafficking to tissues. CD44 is essential for the migration of MSCs into the extracellular matrix. 55 CD44 on the surface of MSC-derived EVs appears to be important for incorporation into injured tissues, which is a critical step for the therapeutic effects.
Ischemia-and reperfusion-induced ALI
Gennai and colleagues 56 used ex vivo perfused human lungs rejected for transplantation treated with MSC-derived EVs as a technique for rehabilitating marginal donor lungs. 57 In the study, IV administration of MSC-derived EVs improved alveolar fluid clearance rate in a dose-dependent manner and decreased lung weight gain or pulmonary edema. MSCderived EVs also increased nitric oxide level in the perfusate, which was associated with improvement of lung compliance and decrease in pulmonary artery pressure and resistance. Furthermore, MSC-derived EVs reduced perfusate pH and lactate level, showing the metabolomic effects of MSC-derived EVs. Finally, coadministration of CD44-neutralizing antibody with MSC-derived EVs abrogated the therapeutic effects on alveolar fluid clearance, lung weight, compliance, and pulmonary artery pressure and resistance, demonstrating the critical role of CD44 in the activity of the EVs.
Other lung disease models 
CONCLUSIONS
In conclusion, besides MSCs, EVs released from human MSCs have therapeutic properties in various preclinical models of ALI. The therapeutic potency of MSC-derived EVs can be equivalent to those of MSCs, and the mechanism of action of MSCs may be also be recapitulated in MSCderived EVs. MSC-derived EVs can be an attractive alternative to MSCs when considering the risk of iatrogenic tumor formation or of pulmonary embolism with IV administration of MSCs. However, many questions will need to be addressed before any serious translation to clinical trials: 1) standardized techniques to characterize and quantify EVs; 2) appropriate assessments for potency to compare between MSC and MSC-derived EVs; 3) whether MSC-derived exosomes, microvesicles, or both are more effective; and 4) cost-effectiveness between the productions for MSC and MSC-derived EVs. Regardless, cell-based therapy with EVs has become a legitimate alternative to using live cells and should be studied further.
